Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (177)Lu-Dotatate in the Phase III NETTER-1 Trial

PURPOSE: Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life (QoL). We assessed the impact of (177)Lu-Dotatate treatment on time to deterioration in health-related QoL. METHODS: The NETTER-1 trial is an international phase III study in patients with midgut NETs...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: Strosberg, Jonathan, Wolin, Edward, Chasen, Beth, Kulke, Matthew, Bushnell, David, Caplin, Martyn, Baum, Richard P., Kunz, Pamela, Hobday, Timothy, Hendifar, Andrew, Oberg, Kjell, Sierra, Maribel Lopera, Thevenet, Thomas, Margalet, Ines, Ruszniewski, Philippe, Krenning, Eric
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2018
Schlagworte:
RAPID COMMUNICATION
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6366953/
https://ncbi.nlm.nih.gov/pubmed/29878866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.78.5865
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge